Denali Therapeutics Inc. (DNLI) vs Nurix Therapeutics, Inc. (NRIX)
- Denali Therapeutics Inc. DNLI 17.56 −4.25%
- Nurix Therapeutics, Inc. NRIX 24.42 −2.12%
Denali Therapeutics Inc. and Nurix Therapeutics, Inc. are both Biotechnology companies. Denali Therapeutics Inc. and Nurix Therapeutics, Inc. are of similar size ($2.9B and $2.7B). Denali Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Nurix Therapeutics, Inc. trades at 9.7×. Nurix Therapeutics, Inc. grew revenue faster over the last twelve months: 738.8% against 194.7%. Nurix Therapeutics, Inc. has the higher net margin (42.0% vs −171.1%) and the higher return on invested capital (0.00% vs −260.5%). Across the 18 metrics below, Nurix Therapeutics, Inc. leads on 17 and Denali Therapeutics Inc. on 1.
Valuation
Profitability
| Metric | DNLI | NRIX | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.97% | 100.00% | 65.16% |
| Operating margin | (181.51%) | 41.27% | 0.00% |
| Net margin | (171.06%) | 42.01% | 0.00% |
| Free cash flow margin | (146.31%) | 52.68% | 0.00% |
| Return on equity | (54.93%) | 43.99% | (56.36%) |
| Return on assets | (44.01%) | 34.33% | (48.04%) |
| Return on invested capital | (260.54%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack